Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)‘s stock had its “buy” rating restated by stock analysts at Mizuho in a report released on Wednesday, Marketbeat Ratings reports. They presently have a $48.00 price objective on the specialty pharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of 127.27% from the company’s current price.

A number of other research analysts have also recently issued reports on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $30.00 target price on shares of Adamas Pharmaceuticals in a research note on Friday, September 1st. They noted that the move was a valuation call. BidaskClub cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Cowen and Company set a $45.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, William Blair reissued an “ourperform” rating on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $36.67.

Shares of Adamas Pharmaceuticals (ADMS) traded up 4.427% during trading on Wednesday, reaching $22.055. The company had a trading volume of 1,071,961 shares. The company’s market cap is $496.55 million. Adamas Pharmaceuticals has a 12-month low of $12.10 and a 12-month high of $23.84. The firm has a 50-day moving average of $18.10 and a 200-day moving average of $17.20.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.12). Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 52.91%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million. During the same quarter last year, the firm posted ($0.78) EPS. The business’s revenue was down 90.9% on a year-over-year basis. On average, equities research analysts anticipate that Adamas Pharmaceuticals will post ($3.79) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/15/adamas-pharmaceuticals-inc-adms-rating-reiterated-by-mizuho.html.

In related news, major shareholder Great Point Partners Llc sold 380,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 21st. The shares were sold at an average price of $17.08, for a total value of $6,490,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 29.00% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC acquired a new stake in Adamas Pharmaceuticals during the 2nd quarter worth $109,000. American International Group Inc. grew its holdings in Adamas Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after acquiring an additional 682 shares during the period. Virtu KCG Holdings LLC acquired a new stake in Adamas Pharmaceuticals during the 2nd quarter worth $184,000. Wells Fargo & Company MN grew its holdings in Adamas Pharmaceuticals by 28.4% during the 1st quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after acquiring an additional 3,358 shares during the period. Finally, Trexquant Investment LP acquired a new stake in Adamas Pharmaceuticals during the 1st quarter worth $287,000. 69.24% of the stock is owned by hedge funds and other institutional investors.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.